Through the collaboration, Lysogene, UMMS and AU will develop IND - supporting preclinical studies in GM1 - gangliosidosis using
AAV gene therapy technology.
In collaboration with the University of Massachusetts Medical School (UMMS) and Auburn University (AU), Lysogene is developing IND - supporting preclinical studies using
AAV gene therapy technology to translate the initial proof of concept into a viable drug development program to the benefit of patients in urgent need.
Kotterman was 4DMT's first hire after working on
its gene therapy technology as a graduate student in Schaffer's lab.
Her postdoctoral research was conducted with a team of CNRS researchers in Paris, France, where she employed biochemical and
gene therapy technologies to investigate the impact of protein aggregation in Parkinson's disease.
In addition to
gene therapy technologies, Dr Verma's major research interests are cellular genes whose alteration can cause or suppress cancer.